UROwebinar: Role of liquid biopsy in identifying mCRPC patients harbouring specific aberrations - A focus on AR-LBD mutations

 This UROwebinar of the European School of Urology and the EAU Section of Oncological Urology will focus on the role of liquid biopsy in detecting androgen receptor ligand-binding domain (AR-LBD) mutations, which are key drivers of resistance to AR pathway inhibitors.

Liquid biopsy is increasingly shaping the management of metastatic castration-resistant prostate cancer (mCRPC), particularly by enabling the identification of actionable molecular alterations. 

The UROwebinar aims to clarify when and how liquid biopsy should be used in clinical practice, how to interpret results, and how these findings can guide treatment selection and sequencing in mCRPC, helping clinicians address real-world challenges in precision oncology.